Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers

v3.19.1
Revenues from Contracts and Significant Customers
 3 Months Ended
Mar. 31, 2019
Revenues [Abstract]  
Revenues From Contracts And Significant Customers
19. Revenues from Contracts and Significant Customers
 
Disaggregation of Total Revenues
 
The Company has three marketed products, Targadox®, Luxamend®, Ceracade® and Exelderm®. Substantially all of the Company’s product revenues are recorded in the U.S. Substantially all of the Company’s collaboration revenues are from its collaboration with TGTX. Revenues by product and collaborator are summarized as follows (in thousands):
 
 
 
Three months ended 
March 31,
 
 
 
2019
 
 
2018
 
Targadox®
 
$
5,700
 
 
$
5,498
 
Other branded revenue
 
 
425
 
 
 
11
 
Total product revenues
 
$
6,125
 
 
$
5,509
 
TGTX
 
 
352
 
 
 
394
 
Total Revenue
 
$
6,477
 
 
$
5,903
 
 
Significant Customers
 
For the three months ended March 31, 2019, one of the Company’s Dermatology Products customers accounted for more than
10.0
% of its total gross product revenue in the amount of $
19.9
million.
 
For the three months ended March 31, 2018, three of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total gross product revenue in the amount of $
4.4
million and $
3.9
million and $
2.0
million, respectively.
 
At March 31, 2019, one of the Company’s Dermatology Products customers accounted for more than 10.0% of its total accounts receivable balance in the amount of $7.7 million.
 
At March 31, 2018, two of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $3.0 million and $2.1 million, respectively.